<\/p>\n
![\"neogap-therapeutics-bio-2026-san-diego.jpg\"](\"https:\/\/www.europesays.com\/se\/wp-content\/uploads\/2026\/04\/b6c9ad3c1fdf9e8d_800x800ar.jpg\"\/)
San Diego, USA \u2013 plats f\u00f6r BIO International Convention 2026, 22\u201325 juni.<\/p>\n
Programmet organiseras av European Innovation Council (EIC), Europas ledande innovationsprogram och st\u00f6rsta investerare inom deep tech. Genom Business Acceleration Services st\u00f6djer EIC innovativa bolag i deras kommersialisering och internationella expansion genom att erbjuda tillg\u00e5ng till globala partnerskap, mentorskap och aff\u00e4rsutvecklingsm\u00f6jligheter.<\/p>\n
Inom ramen f\u00f6r International Trade Fairs Programme \u00e4r Neogap en del av EIC:s paviljong vid BIO International Convention. Som ett av 15 utvalda bolag \u2013 och det enda svenska bolaget i delegationen \u2013 f\u00e5r bolaget tillg\u00e5ng till aff\u00e4rsutvecklingsst\u00f6d, coaching och riktade matchmaking-aktiviteter inf\u00f6r och under konferensen.<\/p>\n
Neogap utvecklar pTTL, en individanpassad cellbaserad immunterapi f\u00f6r behandling av solida tum\u00f6rer. Behandlingen utv\u00e4rderas i en p\u00e5g\u00e5ende klinisk fas I\/II-studie hos patienter med avancerad kolorektalcancer.<\/p>\n
\u201dAtt bli utvalda av EIC till BIO International Convention \u00e4r ett kvitto p\u00e5 att v\u00e5r teknologi och kliniska utveckling v\u00e4cker internationellt intresse. BIO \u00e4r en central m\u00f6tesplats f\u00f6r den globala biotekniksektorn och ger oss en v\u00e4rdefull m\u00f6jlighet att \u00f6ka v\u00e5r synlighet, knyta kontakter och skapa nya aff\u00e4rsm\u00f6jligheter\u201d, s\u00e4ger Samuel Svensson, vd f\u00f6r Neogap Therapeutics.<\/p>\n
BIO International Convention \u00e4ger rum i San Diego den 22\u201325 juni 2026. F\u00f6r mer information:\u00a0https:\/\/convention.bio.org\/<\/a><\/p>\n Om Neogaps cellbaserade immunterapi, pTTL<\/strong>
F\u00f6r mer information, v\u00e4nligen kontakta:<\/strong>
<\/p>\n Om Neogap Therapeutics<\/strong> Taggar:<\/strong><\/p>\n
pTTL (personalised Tumour Trained Lymphocytes) \u00e4r en individanpassad cellbaserad immunterapi som st\u00e4rker patientens egna T-celler f\u00f6r att bek\u00e4mpa cancer. Terapin kombinerar avancerad DNA-sekvensering med expansion av T-celler f\u00f6r att m\u00f6jligg\u00f6ra en precisionsbaserad behandling av solida tum\u00f6rer. Behandlingen bygger p\u00e5 Neogaps propriet\u00e4ra teknologier PIOR\u00ae och EpiTCer\u00ae och utv\u00e4rderas i en p\u00e5g\u00e5ende fas I\/II-studie i patienter med avancerad kolorektalcancer.<\/p>\n![\"EIC-logo-CoFundedBy-CMYK_EN.png\"](\"https:\/\/www.europesays.com\/se\/wp-content\/uploads\/2026\/04\/9c735d2d5a8b54a7_800x800ar.png\")
Project reference number: 190185439 \u2013 NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.<\/p>\n
\n
\n
<\/p>\n
Samuel Svensson, VD\u00a0
Tfn:\u00a0+46 733 54 21 94
E-post: samuel.svensson@neogap.se<\/a><\/p>\n
Neogap Therapeutics \u00e4r ett svenskt bioteknikbolag i klinisk fas som utvecklar individanpassad cancerimmunterapi baserad p\u00e5 patientens egna celler. Terapin bygger p\u00e5 bolagets tv\u00e5 propriet\u00e4ra teknologier, PIOR\u00ae och EpiTCer\u00ae. PIOR\u00ae utnyttjar patientbaserade DNA-sekvenseringsdata och maskininl\u00e4rning f\u00f6r att identifiera tum\u00f6rspecifika mutationer. EpiTCer\u00ae anv\u00e4nds f\u00f6r att expandera T-celler som k\u00e4nner igen och angriper de utvalda tum\u00f6rspecifika m\u00e5lstrukturerna. Neogap \u00e4r verksamt vid Cancercentrum Karolinska i Stockholm. F\u00f6r mer information om Neogap och dess forskning, bes\u00f6k neogap.se<\/a>\u00a0och f\u00f6lj Neogap p\u00e5\u00a0LinkedIn<\/a>.<\/p>\n
\n
\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Neogap Therapeutics, som utvecklar individanpassad immunterapi f\u00f6r cancer, har valts ut av European Innovation…\n","protected":false},"author":2,"featured_media":230484,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[66],"tags":[18049,4352,18047,18048,14921,14922,80,78,79,34,31,33,32,30,81,84,83,82],"class_list":["post-230483","post","type-post","status-publish","format-standard","has-post-thumbnail","category-vetenskap-och-teknik","tag-bio-international-convention-2026","tag-bioteknik","tag-cellterapi","tag-eic","tag-immunterapi","tag-neogap-therapeutics","tag-science","tag-science-and-technology","tag-scienceandtechnology","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish","tag-technology","tag-teknik","tag-vetenskap","tag-vetenskapteknik"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116480544049827810","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/230483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=230483"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/230483\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/230484"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=230483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=230483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=230483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}